These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34330867)

  • 1. Oral Vancomycin as Secondary Prophylaxis for
    Bao H; Lighter J; Dubrovskaya Y; Merchan C; Siegfried J; Papadopoulos J; Jen SP
    Pediatrics; 2021 Aug; 148(2):. PubMed ID: 34330867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Oral Vancomycin for Prevention of Healthcare Facility-Onset Clostridioides difficile Infection in Targeted Patients During Systemic Antibiotic Exposure.
    Johnson SW; Brown SV; Priest DH
    Clin Infect Dis; 2020 Aug; 71(5):1133-1139. PubMed ID: 31560051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population.
    Morrisette T; Van Matre AG; Miller MA; Mueller SW; Bajrovic V; Abidi MZ; Benamu E; Kaiser JN; Barber GR; Chase S; Tobin J; Fish DN; Gutman JA
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):2091-2097. PubMed ID: 31255741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Efficacy of Oral Vancomycin Prophylaxis for the Prevention of
    Knight EM; Schiller DS; Fulman MK; Rastogi R
    J Pharm Pract; 2020 Oct; 33(5):633-639. PubMed ID: 30744479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral vancomycin prophylaxis during systemic antibiotic exposure to prevent Clostridiodes difficile infection relapses.
    Caroff DA; Menchaca JT; Zhang Z; Rhee C; Calderwood MS; Kubiak DW; Yokoe DS; Klompas M
    Infect Control Hosp Epidemiol; 2019 Jun; 40(6):662-667. PubMed ID: 31030679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral vancomycin prophylaxis for the prevention of
    Babar S; El Kurdi B; El Iskandarani M; Haddad I; Imam Z; Alomari M; Myers J; Moorman J
    Infect Control Hosp Epidemiol; 2020 Nov; 41(11):1302-1309. PubMed ID: 32594929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Vancomycin for Secondary Prophylaxis of Clostridium difficile Infection.
    Brown CC; Manis MM; Bohm NM; Curry SR
    Ann Pharmacother; 2019 Apr; 53(4):396-401. PubMed ID: 30450942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Secondary Prophylaxis With Vancomycin for Preventing Recurrent Clostridium difficile Infections.
    Carignan A; Poulin S; Martin P; Labbé AC; Valiquette L; Al-Bachari H; Montpetit LP; Pépin J
    Am J Gastroenterol; 2016 Dec; 111(12):1834-1840. PubMed ID: 27619835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of oral vancomycin prophylaxis for prevention of
    Tariq R; Laguio-Vila M; Tahir MW; Orenstein R; Pardi DS; Khanna S
    Therap Adv Gastroenterol; 2021; 14():1756284821994046. PubMed ID: 33747124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary prophylaxis for Clostridioides difficile infection for patients on non-C. difficile antibiotics: a retrospective cohort study.
    Najjar-Debbiny R; Barnett-Griness O; Arbel A; Cohen S; Weber G; Amar M; Yassin R; Greenfeld I; Shehadeh S; Saliba W
    Microbes Infect; 2024; 26(5-6):105349. PubMed ID: 38719086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral Vancomycin Prophylaxis for Primary and Secondary Prevention of
    Maraolo AE; Mazzitelli M; Zappulo E; Scotto R; Granata G; Andini R; Durante-Mangoni E; Petrosillo N; Gentile I
    Antibiotics (Basel); 2022 Jan; 11(2):. PubMed ID: 35203786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of oral vancomycin treatment duration on rate of
    Kwiatkowski D; Marsh K; Katz A; Papadopoulos J; So J; Major VJ; Sommer PM; Hochman S; Dubrovskaya Y; Arnouk S
    Infect Control Hosp Epidemiol; 2024 Jun; 45(6):717-725. PubMed ID: 38288606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Effectiveness of Vancomycin and Metronidazole for the Prevention of Recurrence and Death in Patients With Clostridium difficile Infection.
    Stevens VW; Nelson RE; Schwab-Daugherty EM; Khader K; Jones MM; Brown KA; Greene T; Croft LD; Neuhauser M; Glassman P; Goetz MB; Samore MH; Rubin MA
    JAMA Intern Med; 2017 Apr; 177(4):546-553. PubMed ID: 28166328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients.
    Fishbein SRS; Hink T; Reske KA; Cass C; Struttmann E; Iqbal ZH; Seiler S; Kwon JH; Burnham CA; Dantas G; Dubberke ER
    mSphere; 2021 Jan; 6(1):. PubMed ID: 33441409
    [No Abstract]   [Full Text] [Related]  

  • 15. Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients.
    Ganetsky A; Han JH; Hughes ME; Babushok DV; Frey NV; Gill SI; Hexner EO; Loren AW; Luger SM; Mangan JK; Martin ME; Smith J; Freyer CW; Gilmar C; Schuster M; Stadtmauer EA; Porter DL
    Clin Infect Dis; 2019 May; 68(12):2003-2009. PubMed ID: 30256954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral vancomycin prophylaxis against recurrent
    Zacharioudakis IM; Zervou FN; Dubrovskaya Y; Phillips MS
    Infect Control Hosp Epidemiol; 2020 Aug; 41(8):908-913. PubMed ID: 32539877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Duration Oral Vancomycin to Treat Clostridioides difficile in Patients With Inflammatory Bowel Disease Is Associated With a Low Rate of Recurrence.
    Lei DK; Ollech JE; Andersen M; Weisshof R; Zmeter N; Sossenheimer P; Rubin DT
    Am J Gastroenterol; 2019 Dec; 114(12):1904-1908. PubMed ID: 31714359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementation of routine Clostridioides difficile infection (CDI) primary prophylaxis in lung transplant recipients.
    Fitzmaurice MG; Hohlfelder B; Srinivas P; Rudoni M; Brizendine KD; Budev M
    Clin Transplant; 2023 Sep; 37(9):e15079. PubMed ID: 37477286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged oral vancomycin for secondary prophylaxis of relapsing Clostridium difficile infection.
    Zhang K; Beckett P; Abouanaser S; Stankus V; Lee C; Smieja M
    BMC Infect Dis; 2019 Jan; 19(1):51. PubMed ID: 30642269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vancomycin Prophylaxis for Prevention of Clostridium difficile Infection Recurrence in Renal Transplant Patients.
    Splinter LE; Kerstenetzky L; Jorgenson MR; Descourouez JL; Leverson GE; Saddler CM; Smith JA; Safdar N; Redfield RR
    Ann Pharmacother; 2018 Feb; 52(2):113-119. PubMed ID: 28844154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.